Currier Rebrands as Alentra, Expands to Full-Service CDMO
Medical device and pharmaceutical firms now have access to integrated design, prototyping, and assembly services.
Updated on Oct. 27, 2026 in Healthcare
Live Poll
Do you trust that corporate rebranding efforts signal better service for the average customer?
Currier has rebranded as Alentra, signaling its transition from a specialized plastics component manufacturer to a comprehensive healthcare contract development and manufacturing organization (CDMO). The move follows a series of acquisitions and service integrations aimed at covering the full product lifecycle for medical and pharmaceutical clients.
Why it matters
This shift highlights a consolidation trend among healthcare suppliers, where manufacturers are increasingly expected to handle end-to-end design, prototyping, and assembly rather than just component production. For operators, this indicates rising demand for integrated supply chain partners capable of managing complex regulatory and development workflows.
The company integrated its operations following the acquisitions of Springboard Manufacturing and MOS Plastics, transitioning into a full-service CDMO model. The scale of the new entity now encompasses development, prototyping, and assembly across the medical and pharmaceutical sectors.
The players
Alentra
A healthcare contract development and manufacturing organization that produces components and assemblies for medical, pharmaceutical, and diagnostic markets.
Springboard Manufacturing
A former independent manufacturing entity acquired to build out the company's prototyping and assembly capabilities.
MOS Plastics
A former plastics component manufacturer acquired to help scale the firm's existing healthcare production footprint.
The details
Alentra functions as a contract development and manufacturing organization that now provides integrated services ranging from initial product design to final assembly. By consolidating its engineering and manufacturing footprint in California, the company aims to streamline the development process for medical device and diagnostic firms. This model reduces the need for manufacturers to engage separate vendors for prototyping and production, effectively centralizing the supply chain.
Timeline
The integration of development and engineering organizations occurred between 2025 and 2026.
The rebranding to Alentra was formally announced on October 27, 2026.
Market Landscape
The rebrand aligns with the industry-wide trend of contract manufacturers consolidating vertical capabilities into end-to-end CDMO service models. This mirrors a shift where healthcare firms increasingly prioritize single-source partners to manage complex design and assembly requirements.
Operators in the medical and pharmaceutical space should evaluate whether their current supply chain relies on fragmented component suppliers or integrated partners. Increased vertical integration by firms like Alentra may signal a shift toward faster development cycles, forcing a reevaluation of existing vendor service agreements.
The takeaway
The evolution of Currier into Alentra underscores the competitive pressure for manufacturers to own the entire product lifecycle. Operators should monitor their vendor contracts to determine if current manufacturing partners have the capability to handle prototyping and assembly as regulatory and design standards tighten.
Further reading
For more on industry consolidation, see the latest updates in Healthcare.
Source note: This article includes information reported by PlasticsToday.
Live Poll
Do you trust that corporate rebranding efforts signal better service for the average customer?
